PL371595A1 - Nowe biomateriały, ich otrzymywanie i zastosowanie - Google Patents

Nowe biomateriały, ich otrzymywanie i zastosowanie

Info

Publication number
PL371595A1
PL371595A1 PL03371595A PL37159503A PL371595A1 PL 371595 A1 PL371595 A1 PL 371595A1 PL 03371595 A PL03371595 A PL 03371595A PL 37159503 A PL37159503 A PL 37159503A PL 371595 A1 PL371595 A1 PL 371595A1
Authority
PL
Poland
Prior art keywords
preparation
novel biomaterials
biomaterials
novel
Prior art date
Application number
PL03371595A
Other languages
English (en)
Other versions
PL215579B1 (pl
Inventor
Lajos Szente
Jozsef Szejtli
György Lajos Kis
Christian Schoch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL371595A1 publication Critical patent/PL371595A1/pl
Publication of PL215579B1 publication Critical patent/PL215579B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PL371595A 2002-04-19 2003-04-17 Sposób otrzymywania osadu, osad otrzymany tym sposobem, kompozycja farmaceutyczna i wyrób medyczny PL215579B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02008809 2002-04-19

Publications (2)

Publication Number Publication Date
PL371595A1 true PL371595A1 (pl) 2005-06-27
PL215579B1 PL215579B1 (pl) 2013-12-31

Family

ID=29225593

Family Applications (1)

Application Number Title Priority Date Filing Date
PL371595A PL215579B1 (pl) 2002-04-19 2003-04-17 Sposób otrzymywania osadu, osad otrzymany tym sposobem, kompozycja farmaceutyczna i wyrób medyczny

Country Status (20)

Country Link
US (3) US20050163853A1 (pl)
EP (1) EP1499361B1 (pl)
JP (1) JP4648632B2 (pl)
KR (1) KR101121675B1 (pl)
CN (1) CN1646171B (pl)
AU (1) AU2003224099B2 (pl)
BR (1) BR0309340A (pl)
CA (1) CA2484100C (pl)
CO (1) CO5611168A2 (pl)
ES (1) ES2392964T3 (pl)
HK (1) HK1073070A1 (pl)
IL (1) IL164627A (pl)
MX (1) MXPA04010325A (pl)
NO (1) NO20044979L (pl)
NZ (1) NZ535810A (pl)
PL (1) PL215579B1 (pl)
PT (1) PT1499361E (pl)
RU (1) RU2321597C2 (pl)
WO (1) WO2003089008A1 (pl)
ZA (1) ZA200407794B (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
EP1706095B1 (en) 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
WO2006011044A1 (en) * 2004-07-22 2006-02-02 Pfizer Products Inc. Amorphous cyclodextrin compositions
US8246949B2 (en) * 2004-10-27 2012-08-21 Aciont, Inc. Methods and devices for sustained in-vivo release of an active agent
EP1787658B1 (en) 2005-11-10 2012-03-14 CHEMI S.p.A. Sustained release formulations of somatostatin analogue inhibitors of growth hormone
US8137512B2 (en) * 2006-09-04 2012-03-20 National Institute Of Advanced Industrial Science And Technology Process for analyzing sample by capillary electrophoresis method
JP2009186445A (ja) * 2008-02-08 2009-08-20 Arkray Inc キャピラリー電気泳動法によるヘモグロビンの分析方法およびそれに用いる試薬
US9121821B2 (en) * 2006-09-04 2015-09-01 National Institute Of Advanced Industrial Science And Technology Process for analyzing sample by capillary electrophoresis method
US20100155242A1 (en) * 2006-09-04 2010-06-24 Arkray, Inc. Method of Analyzing a Sample by Capillary Electrophoresis
EP2400987B1 (en) * 2009-02-25 2014-09-03 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US20110015245A1 (en) * 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
US8389558B2 (en) * 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
ES2533030T3 (es) 2010-03-13 2015-04-07 Eastpond Laboratories Limited Composiciones que enlazan grasa
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
EP4043037A1 (en) 2010-12-31 2022-08-17 Eastpond Laboratories Limited Cellular hydration compositions containing cyclodextrins
US20120171184A1 (en) 2010-12-31 2012-07-05 Lajos Szente Cellular hydration compositions
EP2672828B1 (en) 2011-02-10 2015-04-29 Unilever N.V. Antimicrobial composition
MX356582B (es) 2012-01-18 2018-06-05 Surmodics Inc Recubrimiento para dispositivo medico lubrico con bajo nivel de material particulado.
CA2932532C (en) * 2012-12-04 2021-06-22 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
CN105392480A (zh) * 2013-05-17 2016-03-09 马凯特大学 由离子液体组合物形成的含结构性多糖和大环化合物的复合材料
JP5673756B2 (ja) * 2013-08-20 2015-02-18 東洋紡株式会社 医療用材料
RU2597085C2 (ru) * 2013-11-07 2016-09-10 Федеральное государственное бюджетное учреждение науки Институт биологии моря им. А.В. Жирмунского Дальневосточного отделения Российской академии наук (ИБМ ДВО РАН) Имплантируемый матриксный материал для регенеративной медицины и способ его получения (варианты)
EP3313364B1 (en) 2015-06-24 2019-10-23 Kao Germany GmbH Hair treatment process
US11174447B2 (en) 2015-12-29 2021-11-16 Surmodics, Inc. Lubricious coatings with surface salt groups
US10342898B2 (en) * 2015-12-29 2019-07-09 Surmodics, Inc. Lubricious coatings with surface salt groups
WO2018075614A1 (en) 2016-10-18 2018-04-26 Marquette University Composite materials containing structural polymers and photoreactive nitric odide releasing agents and uses thereof for wound dressings
EP4132294A1 (en) 2020-04-06 2023-02-15 Eastpond Laboratories Limited Compositions for promoting cellular hydration
CN114344557A (zh) * 2022-01-10 2022-04-15 山东万容生物科技有限公司 一种含环糊精的水胶体敷料及其制备方法
WO2023212740A1 (en) * 2022-04-29 2023-11-02 Drexel University Surfactant-impregnated mof-coated fabric for antimicrobial applications

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE670837A (pl) * 1964-10-14 1966-01-31
JPS61251616A (ja) * 1985-04-30 1986-11-08 Agency Of Ind Science & Technol 溶質の放出量の制御方法
JPS6416728A (en) * 1987-07-07 1989-01-20 Santen Pharmaceutical Co Ltd Aqueous preparation
JPH03234770A (ja) * 1990-02-09 1991-10-18 Nippon Shokubai Kagaku Kogyo Co Ltd 電気刺激応答性ゲルの製法
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
SE9303627D0 (sv) * 1993-11-03 1993-11-03 Kabi Pharmacia Ab Method and means for prevention of cataract
JPH08134134A (ja) * 1994-11-09 1996-05-28 Nippon Shokubai Co Ltd 粒子状含水ゲル重合体の乾燥方法
JP3297969B2 (ja) * 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
TW434023B (en) * 1995-09-18 2001-05-16 Novartis Ag Preserved ophthalmic composition
JPH0995413A (ja) * 1995-09-29 1997-04-08 Shiseido Co Ltd 皮膚外用剤
GB9718568D0 (en) * 1997-09-03 1997-11-05 Chauvin Pharmaceuticals Limite Compositions
WO2000004916A1 (en) * 1998-07-23 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Encapsulation of water soluble peptides
AU2608800A (en) * 1999-01-12 2000-08-01 Vito-Mannan Polysaccharide L.L.C. Method of isolating mucilaginous polysaccharides and uses thereof
JP2001318350A (ja) * 2000-05-11 2001-11-16 Lion Corp コンタクトレンズ用溶液
MXPA02011254A (es) * 2000-05-15 2003-03-10 Procter & Gamble Composiciones que comprenden ciclodextrina.
US20020147232A1 (en) * 2000-05-26 2002-10-10 Claus Sundgreen Pharmaceutical compositions comprising desglymidodrine as an active drug substance
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
AU2002213429A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds

Also Published As

Publication number Publication date
IL164627A (en) 2009-11-18
KR101121675B1 (ko) 2012-03-13
IL164627A0 (en) 2005-12-18
ZA200407794B (en) 2006-02-22
RU2004133887A (ru) 2005-10-20
PT1499361E (pt) 2012-11-22
NZ535810A (en) 2007-11-30
WO2003089008A1 (en) 2003-10-30
AU2003224099B2 (en) 2006-11-09
CN1646171A (zh) 2005-07-27
JP2005529879A (ja) 2005-10-06
US20050163853A1 (en) 2005-07-28
EP1499361B1 (en) 2012-08-08
BR0309340A (pt) 2005-03-08
AU2003224099A1 (en) 2003-11-03
RU2321597C2 (ru) 2008-04-10
US20080299166A1 (en) 2008-12-04
NO20044979L (no) 2004-11-16
CA2484100A1 (en) 2003-10-30
HK1073070A1 (en) 2005-09-23
CN1646171B (zh) 2010-05-26
CA2484100C (en) 2012-01-03
KR20040103968A (ko) 2004-12-09
PL215579B1 (pl) 2013-12-31
ES2392964T3 (es) 2012-12-17
JP4648632B2 (ja) 2011-03-09
US20120040901A1 (en) 2012-02-16
MXPA04010325A (es) 2005-06-08
EP1499361A1 (en) 2005-01-26
CO5611168A2 (es) 2006-02-28

Similar Documents

Publication Publication Date Title
HK1073070A1 (en) Novel biomaterials, their preparation and use
TWI371450B (en) Novel substituted dihydro 3-halo-1h-pyrazole-5-carboxylates,their preparation and use
IL168102A0 (en) Chk-, pdk-and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
EP1539941A4 (en) ADZYMES AND THEIR USES
IL172222A0 (en) Aryl-heteroaromatic products, compositions comprising them and use
EP1617807A4 (en) SUBSTITUTED 1,4-DIAZEPINE AND ITS USES
HK1059229A1 (en) Cartilage implant and preparation thereof
HK1074446A1 (en) 3-phenyl substituted pyridoindolone, preparation and therapeutic use thereof
HK1081954A1 (en) Novel 1,4-diazabicycloalkane derivatives, their preparation and use
GB0114399D0 (en) Substrates, biomaterials and methods
HUP0500871A3 (en) 5-aryltetrazole compounds, compositions thereof and their use
AU2003296369A8 (en) Imminoamines and preparation thereof
HUP0600238A3 (en) Benzothiazole- and benzoxazole-4,7-dione derivatives and their use
AU2003217565A8 (en) Polydioxaborines, their monomers and their preparation
AU2003231827A8 (en) Pseudo-tissues and uses thereof
EP1517879A4 (en) AMINOALKYLPHENOLS AND METHODS OF USE AND MANUFACTURE
GB0228525D0 (en) Polymers and their use
EP1660088A4 (en) PYRIDOMORPHINANES, PYRIDAZINOMORPHINANES AND USE THEREOF
AU2003299336A8 (en) Diphosphines, preparation and uses thereof
IL151980A0 (en) Resistin binding proteins, their preparation and use
IL149851A0 (en) Resistin binding proteins, their preparation and use
GB0229445D0 (en) Process,composition and use
AU2003219313A1 (en) Chemokines and uses thereof
GB2420345B (en) 3-alpha-glycosyl alpha, alpha-trehaloses their preparation and use
GB0326138D0 (en) Polymers, their preparation and uses